DISCLAIMER
The Diabetes Québec Toolbox is intended for Québec healthcare professionals only. By accessing this web application, you confirm that you are a healthcare professional. The information in the Toolbox is provided for general information purposes only and is not comprehensive. Under no circumstances can Diabetes Québec be held responsible for any error or omission or be prosecuted for any reason whatsoever.
Classes
Oral and Non Insulin Agents
BIGUANIDES
Oral medications

Metformin
Glucophage®
500 mg - 850 mg
OD to TID
Maximum daily dose: 2550mg
Covered
Characteristics and clinical considerations
Product Monograph

Metformin ER
Glumetza®
500 mg - 1000mg
OD
Maximum daily dose: 2000 mg
Not Covered / Private Coverage Private coverage
Characteristics and clinical considerations
Product Monograph

ALPHA-GLUCOSIDASE INHIBITOR
Oral medications

Acarbose
Glucoba™️
50 mg - 1000mg
OD to TID
Maximum daily dose: 300 mg
Covered
How to initiate
Characteristics and clinical considerations
Product Monograph

DPP-4 INHIBITORS
Oral medications

Alogliptin
Nesina®
6.25 mg - 12.5 mg - 25 mg
OD
Code EN148-149-167
Characteristics and clinical considerations
Product Monograph

Alogliptin and Metformin
Kazano™️
12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Linagliptin
Trajenta®
5 mg
OD
Code EN148-167
Characteristics and clinical considerations
Product Monograph

Linagliptin and Metformin
Jentadueto™️
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Saxagliptin
Onglyza®
2.5 mg - 5 mg
OD
Code EN148-149
Characteristics and clinical considerations
Product Monograph

Saxagliptin and Metformin
Komboglyze®
2.5 mg/500 mg - 2.5 mg/850 mg - 2.5 mg/1000 mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Sitagliptin
Januvia®
25 mg - 50 mg - 100 mg
OD
Code EN148-167
Characteristics and clinical considerations
Product Monograph

Sitagliptin and Metformin
Janumet®
50 mg/500 mg - 50 mg/850 mg - 50 mg/1000mg
BID
Code EN150
Characteristics and clinical considerations
Product Monograph

Sitagliptin and Metformin ER
Janumet® XR
50 mg/500 mg - 50 mg/1000 mg - 100 mg/1000 mg
OD
Code EN150
Characteristics and clinical considerations
Product Monograph

SGLT2 INHIBITORS
Oral medications

Canagliflozin
Invokana®
100 mg - 300 mg
OD
Code EN148-149-167
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Canagliflozin and Metformin
Invokamet®
50 mg/500 mg - 50 mg/1000 mg - 150 mg/500 mg - 150 mg/1000 mg
BID
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Dapagliflozin
Forxiga®
5 mg - 10 mg
OD
Code EN148-149 - Code CV399
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Dapagliflozin and Metformin
Xigduo®
5 mg /850 mg - 5 mg/1000 mg
BID
Code EN150
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Empagliflozin
Jardiance®
10 mg - 25 mg
OD
Code EN148-167-179
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Empagliflozin and Linagliptin
Glyxambi🅪
10 mg/5 mg - 25 mg/5 mg
OD
Not Covered / Private coverage
Product Monograph
Cardio-renal protection clinical data
Characteristics and clinical considerations

Empagliflozin and Metformin
Synjardy🅪
5 mg/500 mg - 5 mg/850 mg - 5 mg/1000 mg - 12.5 mg/500 mg - 12.5 mg/850 mg - 12.5 mg/1000 mg
BID
Code EN219
Product Monograph
Cardio-renal protection clinical data
Characteristics and clinical considerations

INSULIN SECRETAGOGUES
Oral medications

Gliclazide
Diamicron®
80 mg
OD to BID
Maximum daily dose : 320 mg
Covered
Characteristics and clinical considerations
Product Monograph

Gliclazide Modified Release
Diamicron®MR
30 mg - 60 mg
OD
Maximum daily dose: 120 mg
Covered
Characteristics and clinical considerations
Product Monograph

Glimepiride
Amaryl®
1 mg - 2 mg- 4 mg
OD to BID
Maximum daily dose: 8 mg
Code EN23
Characteristics and clinical considerations
Product Monograph

Glyburide
Diabeta®
2.5 mg - 5 mg
OD to BID
Maximum daily dose: 20 mg
Covered
Characteristics and clinical considerations
Product Monograph

Repaglinide
GlucoNorm®
0.5 mg - 1 mg - 2 mg
OD to TID AC
Maximum daily dose: 16 mg
Covered
Characteristics and clinical considerations
Product Monograph

THIAZOLIDINEDIONES (TZD)
Oral medications

Pioglitazone
Actos®
15 mg - 30 mg - 45 mg
OD
Code EN117-118-119-121
Characteristics and clinical considerations
Product Monograph

Rosiglitazone
Avandia®
2 mg- 4 mg - 8 mg
OD
Code EN117-118-119-121
Characteristics and clinical considerations
Product Monograph

GLP-1R AGONISTS and GIP
Injectable medications s/c

Tirzepatide
Mounjaro🅪
2.5 mg - 5 mg - 7.5 mg - 10 mg - 12.5 mg - 15 mg (0.5 ml per vial, single-dose vial)
Once-Weekly
Stability at room temperature: 21 days
Private coverage
Complet Web Site
Instruction for use
Patient Brochure
Injection Training Video
Product Monograph

GLP-1R AGONISTS
Injectable medications s/c

Dulaglutide
Trulicity®
0.75 mg - 1.5 mg
(3.5 and 4.5 mg not yet available for purchase in Canada )
Once-Weekly
Stability at room temperature: 14 days
Private coverage ou RAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Instructions for Use - Video
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Liraglutide
Victoza®
0.6 mg - 1.2 mg- 1.8 mg
OD
Stability at room temperature: 30
Private coverage ou RAMQ (according to criteria) - Online Request Only
(Infolettre RAMQ)
Video demo. of the injection technic
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Lixisenatide
Adlyxine™️
10 µg/dose (0.05 mg/ml)
20 µg/dose (0.1mg/ml)
OD
Stability at room temperature: 14 days
Not Covered / Private coverage
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Semaglutide(s/c)
Ozempic®
0.25 mg - 0.5 mg - 1 mg
(2 mg approved in Canada but not yet available for purchase)
Once-Weekly
Stability at room temperature: 8 weeks
Private coverage or RAMQ (according to criteria)
(Infolettre RAMQ)
Video demo. of the injection technic (8 languages)
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph
Multilingual treatment guide
Supply Difficulties (FR)
New 3 mL pen

Semaglutide (s/c)
Wegovy™️ Obesity (≧ 30 BMI) et DB2 (≧ 27 BMI)
0.25 mg - 0.5 mg - 1 mg - 1.7 mg - 2.4 mg (Approved in Canada but not yet available for purchase)
Once-Weekly
Conservation: 8 weeks
Private coverage(when available)
Product Monograph

Semaglutide(oral)
Rybelsus®
3 mg - 7 mg - 14mg
OD
Private coverage or RAMQ (according to criteria) - Online Request Only
Patient Guide
Getting Started
Cardio-renal protection clinical data
Characteristics and clinical considerations
Product Monograph

Glargine U100 (100 units/ml) / Lixisenatide (33 mcg/ml)
Soliqua™️
Maximum recommended daily dose is 60 units:
Glargine U100 60 units / Lixisenatide 20 mcg
Not Covered / Private coverage
How to Inject (video)
How to Inject (pdf)
Therapy Initiation and Titration
Cardio-renal protection clinical data
Characteristics and clinical considerations

Degludec (100 units/ml) / Liraglutide (3.6 mg/ml)
Xultophy®
Maximum recommended daily dose is 50 units:
Degludec 50 units / Liraglutide 1.8 mg
Not Covered / Private coverage
Therapy Initiation and Titration
Cardio-renal protection clinical data
Characteristics and clinical considerations Product Monograph